(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 38.43% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Tg Therapeutics's revenue in 2024 is $233,662,000.On average, 4 Wall Street analysts forecast TGTX's revenue for 2024 to be $39,346,412,706, with the lowest TGTX revenue forecast at $37,023,924,295, and the highest TGTX revenue forecast at $42,373,059,837. On average, 4 Wall Street analysts forecast TGTX's revenue for 2025 to be $64,119,673,895, with the lowest TGTX revenue forecast at $50,483,238,782, and the highest TGTX revenue forecast at $83,433,543,112.
In 2026, TGTX is forecast to generate $97,092,832,499 in revenue, with the lowest revenue forecast at $63,107,136,893 and the highest revenue forecast at $122,764,513,740.